Acetylcholinesterase inhibitors in myasthenia gravis: To be or not to be?

Muscle and Nerve

Volumn 39, Issue 6, 2009, Pages 724-728

  Punga, Anna Rostedt ^a   Stålberg, Erik ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acetylcholinesterase inhibitors; AChEI; MG; MuSK; Neuromuscular

Indexed keywords

AMBENONIUM; ANTISENSE OLIGODEOXYNUCLEOTIDE; CHOLINERGIC RECEPTOR ANTIBODY; CHOLINESTERASE INHIBITOR; EDROPHONIUM; EN 101; NEOSTIGMINE; PHYSOSTIGMINE; PROTEIN TYROSINE KINASE; PYRIDOSTIGMINE; UNCLASSIFIED DRUG; ACETYLCHOLINE; ACETYLCHOLINESTERASE; CHOLINERGIC RECEPTOR; EN101; IMMUNOLOGIC FACTOR; OLIGODEOXYRIBONUCLEOTIDE;

CLINICAL TRIAL; DIARRHEA; DRUG MECHANISM; DRY EYE; ELECTROMYOGRAPHY; ENZYME INHIBITION; FASCICULATION; HUMAN; HYPERHIDROSIS; IMMUNOMODULATION; IMMUNOREGULATION; LACRIMATION DISORDER; MUSCLE CRAMP; MUSCLE FATIGUE; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NONHUMAN; PRIORITY JOURNAL; PTOSIS; REVIEW; SALIVATION DISORDER; STOMACH PAIN; XEROSTOMIA; ANIMAL; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; GENETICS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY;

ACETYLCHOLINE; ACETYLCHOLINESTERASE; ANIMALS; CHOLINESTERASE INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSION; MYASTHENIA GRAVIS; NEUROMUSCULAR JUNCTION; OLIGODEOXYRIBONUCLEOTIDES; RECEPTORS, CHOLINERGIC;

EID: 67049165109     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21319     Document Type: Review

References (44)

1. Araki S, Uchino M, Kumamoto T. Prevalence studies of multiple sclerosis, myasthenia gravis, and myopathies in Kumamoto district, Japan. Neuroepidemiology 1987;6:120-129. (Pubitemid 17128565)
2. Argov Z, McKee D, Agus S, Brawer S, Shlomowitz N, Yoseph OB, et al. Treatment of human myasthenia gravis with oral antisense suppression of acetylcholinesterase. Neurology 2007;69:699-700. (Pubitemid 47256014)
3. Ben Aziz-Aloya R, Seidman S, Timberg R, Sternfeld M, Zakut H, Soreq H. Expression of a human acetylcholinesterase promoter- reporter construct in developing neuromuscular junctions of Xenopus embryos. Proc Natl Acad Sci U S A 1993;90:2471-2475. (Pubitemid 23078649)
4. Boneva N, Hamra-Amitay Y, Wirguin I, Brenner T. Stimulated- single fiber electromyography monitoring of antisense induced changes in experimental autoimmune myasthenia gravis. Neurosci Res 2006;55:40-44.
5. Brenner T, Hamra-Amitay Y, Evron T, Boneva N, Seidman S, Soreq H. The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis. FASEB J 2003;17:214-222. (Pubitemid 36164391)
6. Drachman DB, Adams RN, Josifek LF, Pestronk A, Stanley EF. Antibody-mediated mechanisms of ACh receptor loss in myasthenia gravis: clinical relevance. Ann N Y Acad Sci 1981;377:175-188.
7. Engel AG, Lambert EH, Santa T. Study of long-term anticholinesterase therapy. Effects on neuromuscular transmission and on motor end-plate fine structure. Neurology 1973;23:1273-1281.
8. Engel AG, Lambert EH, Howard FM. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc 1977;52:267-280. (Pubitemid 8113467)
9. Evoli A, Tonali PA, Padua L, Monaco ML, Scuderi F, Batocchi AP, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003;126(Pt 10):2304-2311. (Pubitemid 37432373)
10. Fujii T, Kawashima K. YM905, a novel M3 antagonist, inhibits Ca2+ signaling and c-fos gene expression mediated via muscarinic receptors in human T cells. Gen Pharmacol 2000;35:71-75. (Pubitemid 33052465)
11. Heilbronn E, Mattsson C, Stålberg E. Immune response in rabbits to a cholinergic receptor protein: possibly a model for myasthenia gravis. Medica Int Congr Series Recent Advances Myologi 1974;360:486-492.
12. Hilton-Brown P, Stålberg E, Osterman PO. Signs of reinnervation in myasthenia gravis. Muscle Nerve 1982;5:215-221.
13. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-368. (Pubitemid 32224355)
14. Huang D, Shi FD, Giscombe R, Zhou Y, Ljunggren HG, Lefvert AK. Disruption of the IL-1beta gene diminishes acetylcholine receptor-induced immune responses in a murine model of myasthenia gravis. Eur J Immunol 2001;31:225-232. (Pubitemid 32098001)
15. Hudson CS, Rash JE, Tiedt TN, Albuquerque EX. Neostigmine- induced alterations at the mammalian neuromuscular junction. II. Ultrastructure. J Pharmacol Exp Ther 1978;205:340-356. (Pubitemid 8357780)
16. Kamimura Y, Fujii T, Kojima H, Nagano T, Kawashima K. Nitric oxide (NO) synthase mRNA expression and NO production via muscarinic acetylcholine receptor-mediated pathways in the CEM, human leukemic T-cell line. Life Sci 2003;72:2151-2154. (Pubitemid 36298961)
17. Kaufer D, Friedman A, Seidman S, Soreq H. Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature 1998;393:373-377. (Pubitemid 28269711)
18. Kawashima K, Fujii T. The lymphocytic cholinergic system and its biological function. Life Sci 2003;72:2101-2109. (Pubitemid 36298953)
19. Lefvert AK, Cuenoud S, Fulpius BW. Binding properties and subclass distribution of anti-acetylcholine receptor antibodies in myasthenia gravis. J Neuroimmunol 1981;1:125-135. (Pubitemid 11088030)
20. Lev-Lehman E, Evron T, Broide RS, Meshorer E, Ariel I, Seidman S, et al. Synaptogenesis and myopathy under acetylcholinesterase overexpression. J Mol Neurosci 2000;14:93-105. (Pubitemid 30368304)
21. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976;26:1054-1059.
22. Massoulie J, Pezzementi L, Bon S, Krejci E, Vallette FM. Molecular and cellular biology of cholinesterases. Prog Neurobiol 1993;41:31-91. (Pubitemid 23140755)
23. Meshorer E, Erb C, Gazit R, Pavlovsky L, Kaufer D, Friedman A, et al. Alternative splicing and neuritic mRNA translocation under long-term neuronal hypersensitivity. Science 2002;295:508-512. (Pubitemid 34101643)
24. Millard CB, Broomfield CA. Anticholinesterases: medical applications of neurochemical principles. J Neurochem 1995;64:1909-1918.
25. Nizri E, Hamra-Amitay Y, Sicsic C, Lavon I, Brenner T. Antiinflammatory properties of cholinergic up-regulation: a new role for acetylcholinesterase inhibitors. Neuropharmacology 2006;50:540-547.
26. Oosterhuis HJGH, Oosterhuis HJGH. Myasthenia gravis. Groningen, Netherlands: Groningen Neurological Press; 1997.
27. Osserman KE, Teng P, Kaplan LI. Studies in myasthenia gravis; preliminary report on therapy with mestinon bromide. JAMA 1954;155:961-965.
28. Phillips LH. The epidemiology of myasthenia gravis. Ann N Y Acad Sci 2003;998:407-412. (Pubitemid 37194192)
29. Punga AR, Flink R, Askmark H, Stålberg EV. Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody. Muscle Nerve 2006;34:111-115.
30. Punga AR, Sawada M, Stålberg EV. Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis. Muscle Nerve 2008;37:300-307. (Pubitemid 351304789)
31. Rostedt Punga A, Ahlqvist K, Bartoccioni E, Scuderi F, Marino M, et al. Neurophysiological and mitochondrial abnormalities in MuSK antibody seropositive myasthenia gravis compared to other immunological subtypes. Clin Neurophysiol 2006;117:1434-1443. (Pubitemid 43947705)
32. Sanders D. Neuromuscular junction disorders. Daube JaMF, editor. Amsterdam: Elsevier; 2003. p 507-529.
33. Sanes JR, Hall ZW. Antibodies that bind specifically to synaptic sites on muscle fiber basal lamina. J Cell Biol 1979;83(2 Pt 1):357-370. (Pubitemid 10205719)
34. Schwab RS. The pharmacologic basis of the treatment of myasthenia gravis. Pharmacol Ther 1960;1:319-336.
35. Shapira M, Tur-Kaspa I, Bosgraaf L, Livni N, Grant AD, Grisaru D, et al. A transcription-activating polymorphism in the ACHE promoter associated with acute sensitivity to antiacetylcholinesterases. Hum Mol Genet 2000;9:1273-1281. (Pubitemid 30312476)
36. Shigemoto K, Kubo S, Maruyama N, Hato N, Yamada H, Jie C, et al. Induction of myasthenia by immunization against muscle- specific kinase. J Clin Invest 2006;116:1016-1024.
37. Stålberg E, Trontelj JV. Single fiber electromyography in healthy and diseased muscle. New York: Raven Press; 1994. p 1-291.
38. Sternfeld M, Ming G, Song H, Sela K, Timberg R, Poo M, et al. Acetylcholinesterase enhances neurite growth and synapse development through alternative contributions of its hydrolytic capacity, core protein, and variable C termini. J Neurosci 1998;18:1240-1249. (Pubitemid 28082410)
39. Storm-Mathisen A. Epidemiology of myasthenia gravis in Norway. Acta Neurol Scand 1984;70:274-284. (Pubitemid 14018371)
40. Tiedt TN, Albuquerque EX, Hudson CS, Rash JE. Neostigmine- induced alterations at the mammalian neuromuscular junction. I. Muscle contraction and electrophysiology. J Pharmacol Exp Ther 1978;205:326-339. (Pubitemid 8357780)
41. Walker M. Case showing the effect of prostigmine on myasthenia gravis. Proc R Soc Med 1935;28:33-35.
42. van Dijk JG, Lammers GJ, Wintzen AR, Molenaar PC. Repetitive CMAPs: mechanisms of neural and synaptic genesis. Muscle Nerve 1996;19:1127-1133.
43. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985;48:1246-1252. (Pubitemid 16229407)
44. Xu K, Jha S, Hoch W, Dryer SE. Delayed synapsing muscles are more severely affected in an experimental model of MuSK-induced myasthenia gravis. Neuroscience 2006;143:655-659. (Pubitemid 44751373)